argenx SE ARGX

Morningstar Rating
€501.00 +4.30 (0.87%)
View Full Chart

Company Report

Argenx Is Expanding Its Autoimmune Portfolio With New Vyvgart Approvals and Pipeline Candidates

Dutch biotech Argenx is hoping to build a portfolio of autoimmune treatments around Vyvgart, which received FDA approval in 2021 as a treatment for myasthenia gravis. We think the drug will see peak sales of more than $9 billion if approvals can extend into new autoimmune indications in neurology, hematology, dermatology, and nephrology over the next several years, although competitors in testing and uncertainty around future clinical trial results for Vyvgart prevent us from assigning the firm an economic moat.

Price vs Fair Value

ARGX is trading at a 699% premium.
Price
€496.70
Fair Value
€113.00
Uncertainty
Very High
1-Star Price
€873.74
5-Star Price
€483.90
Economic Moat
Whm
Capital Allocation
Fmtltmq

Bulls Say, Bears Say

Bulls

Novel FcRn inhibitor Vyvgart is a pipeline in a product, currently approved in myasthenia gravis and CIDP but in testing in multiple additional indications.

Bears

Vyvgart’s initial average price in myasthenia gravis of $225,000 per year per patient in the US could fall over time, as international launches progress and as competitors reach the market.

News

Trading Information

Previous Close Price
€496.70
Day Range
€496.30502.40
52-Week Range
€271.00502.40
Bid/Ask
€500.80 / €501.20
Market Cap
€29.96 Bil
Volume/Avg
8,333 / 59,358

Key Statistics

Price/Earnings (Normalized)
Price/Sales
19.64
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield

Company Profile

Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Mid Growth
Total Number of Employees
1,148

Competitors

Valuation

Metric
ARGX
JNJ
CSL
Price/Earnings (Normalized)
15.3830.00
Price/Book Value
7.475.425.37
Price/Sales
19.644.586.24
Price/Cash Flow
17.3933.17
Price/Earnings
ARGX
JNJ
CSL

Financial Strength

Metric
ARGX
JNJ
CSL
Quick Ratio
7.520.770.87
Current Ratio
8.531.072.18
Interest Coverage
−229.7424.458.01
Quick Ratio
ARGX
JNJ
CSL

Profitability

Metric
ARGX
JNJ
CSL
Return on Assets (Normalized)
−0.02%13.17%7.82%
Return on Equity (Normalized)
−0.02%32.42%17.33%
Return on Invested Capital (Normalized)
−3.09%20.93%10.52%
Return on Assets
ARGX
JNJ
CSL

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk AS ADR
NVO
XzppymgkcGkjcm$518.0 Bil
Vertex Pharmaceuticals Inc
VRTX
JdgdzmvyPvdsrhy$119.3 Bil
Regeneron Pharmaceuticals Inc
REGN
StltfsrCjqfxp$114.7 Bil
Alnylam Pharmaceuticals Inc
ALNY
MdqrkznvtDzrrz$34.9 Bil
argenx SE ADR
ARGX
SyngdjqpJbx$32.9 Bil
BioNTech SE ADR
BNTX
ZqdrvfhzWbpp$28.3 Bil
Moderna Inc
MRNA
BqcpkdlvNsx$24.3 Bil
United Therapeutics Corp
UTHR
RsrfqgpzWdbmm$15.7 Bil
Biomarin Pharmaceutical Inc
BMRN
FjfpyjqgJxbbwr$13.3 Bil
Incyte Corp
INCY
KbzymzfTnykw$13.0 Bil

Sponsor Center